A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis

Summary

This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details included a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (4 weeks ± 3 days). The total number of study visits was 7.

Timeline

Start

2023-10-26

Primary completion

2024-11-13

Completion

2024-12-11

Drugs

Indications